Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA immunotoxin (inactive mutant)
- Development stage
- Discontinued
- Lead developer
- National Cancer Institute
- Modality
- Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-BCMA immunotoxin (inactive mutant) is a recombinant immunotoxin (RIT) used as a negative control in preclinical research for the treatment of multiple myeloma. Developed by researchers at the National Cancer Institute (NCI), it consists of an antibody fragment (Fv or Fab) targeting B-cell maturation antigen (BCMA) fused to a truncated version of Pseudomonas exotoxin A (PE). The toxin domain contains a specific E553D mutation that completely abolishes its ADP-ribosylation activity, rendering the compound non-cytotoxic. It serves as a critical tool in scientific experiments to verify that the efficacy of active BCMA-targeting immunotoxins, such as LMB-70 and LMB-75, is derived from the delivery of a functional toxin rather than simple target binding or non-specific effects.
- Other names
- anti-BCMA RIT (inactive mutant)anti-BCMA-PE (E553D)anti-BCMA Fab-PE38 (inactive mutant)anti-BCMA dsFv-PE38 (inactive mutant)
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA immunotoxin (inactive mutant).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA immunotoxin (inactive mutant).